Participation bias

Enable Medicine Identifies Sex-Dependent Differences in Resistance to Common Treatment for Ulcerative Colitis

Retrieved on: 
Tuesday, January 24, 2023
Cloud, UC, TNF, TNF inhibitor, Participation bias, Colitis, Atlas, Stanford University, University of California, San Diego, IBD, Female, Cancer, Science Advances, Medicine, Patient, Risk, Infection, Ulcerative colitis, Autoimmunity, Pharmaceutical industry, Medical imaging

In the paper the researchers identified cellular signatures that indicate resistance to TNF inhibitor (TNFi) therapy, the front-line treatment for ulcerative colitis (UC).

Key Points: 
  • In the paper the researchers identified cellular signatures that indicate resistance to TNF inhibitor (TNFi) therapy, the front-line treatment for ulcerative colitis (UC).
  • Combined direct and indirect costs caused by ulcerative colitis are estimated at $45 billion per year in the United States and Europe.
  • The paper identifies sex-related differences in the frequency of specific cellular signatures in untreated patients.
  • Notably, this is the most comprehensive spatial atlas of ulcerative colitis released by researchers to date.